- SEK79.82m
- SEK56.31m
Brief: Vivesto Says Topline Results For Paccal Vet 'Positive'
Brief: Vivesto Q2 Operating Loss At SEK 8.6 Mln
Brief: Vivesto: Positive Results From Exploratory Study With Cantrixil
Brief: Vivesto Appoints Björn Svanström As CFO
Brief: Vivesto Sets Record Date For Reverse Share Split As May 21, 2026
Brief: Vivesto Q1 Operating Result Of SEK -6.8 Mln
Brief: Vivesto Board Proposes Reverse Share Split
Brief: Vivesto Q4 Operating Loss At SEK 8.9 Million
Brief: Vivesto To Carry Out Directed Share Issue
Brief: Vivesto To Receive SEK 53.8 Mln Before Issue Costs From Rights Issue
Brief: Vivesto Approves Issue Of 538,043,455 Shares
Brief: Vivesto Signs Liberi Group To Accelerate Partnering Activities
Brief: Vivesto Resolves On New Share Issue For SEK 53.8 Mln
Brief: Vivesto Q3 Operating Loss At SEK 7.1 Mln
Brief: Vivesto Reports Positive Interim Results For Paccal Vet Pilot Study In Dogs
Brief: Vivesto Announces Positive Preclinical Results For Cantrixil In AML
Brief: Vivesto Q2 Operating Loss Narrows To SEK 9.7 Mln
Brief: Vivesto Q1 Operating Loss SEK 8.6 Mln
Brief: Vivesto Announces Positive Preclinical Data For Cantrixil In Hematological Cancer